Dec 3, 2025 07:30AM Cognition Therapeutics completes enrollment in expanded access program

Nov 6, 2025 08:13AM Cognition Therapeutics, Inc. (CGTX) Tops Q3 EPS by 4c

Sep 3, 2025 07:30AM Cognition Therapeutics reaches 75% enrollment in Alzheimer's drug trial

Aug 12, 2025 04:05PM Cognition Therapeutics, Inc. (CGTX) Reports In-Line Q2 EPS

Jul 21, 2025 07:31AM Cognition Therapeutics publishes zervimesine study data

Jul 14, 2025 07:07AM H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)

Jul 10, 2025 07:31AM Cognition Therapeutics meets with FDA on alzheimer's drug trial path

Jul 3, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)

Jul 1, 2025 07:31AM Cognition Therapeutics (CGTX) Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target

Jun 26, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)

Jun 9, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)

May 27, 2025 06:38AM Cognition Therapeutics (CGTX) PT Lowered to $3 at H.C. Wainwright

May 8, 2025 07:31AM Cognition Therapeutics, Inc. (CGTX) Reports Topline Results Showing Oral CT1812 Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy

May 7, 2025 07:31AM Cognition Therapeutics, Inc. (CGTX) Misses Q1 EPS by 3c

Apr 1, 2025 07:31AM Cognition Therapeutics (CGTX) Presents Results Showing Impact of Zervimesine on Alzheimer’s Disease Processes

Mar 25, 2025 07:31AM Cognition Therapeutics (CGTX) to Report Biomarker Results from Phase 2 SHINE Study

Mar 24, 2025 06:42AM Cognition Therapeutics (CGTX) PT Lowered to $5 at H.C. Wainwright

Mar 21, 2025 06:43AM Cognition Therapeutics (CGTX) PT Lowered to $7 at Brookline Capital Markets

Mar 12, 2025 04:06PM Cognition Therapeutics, Inc. (CGTX) Granted Extension to Regain Nasdaq Compliance

Feb 27, 2025 07:34AM Cognition Therapeutics (CGTX) Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Feb 26, 2025 07:00AM Cognition Therapeutics, Inc. (CGTX) Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of CT1812

Feb 20, 2025 07:31AM Cognition Therapeutics (CGTX) Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine

Dec 19, 2024 06:40AM Cognition Therapeutics (CGTX) PT Raised to $6 at H.C. Wainwright

Dec 18, 2024 07:23AM Cognition Therapeutics (CGTX) Reports Positive Results in Phase 2 Study of CT1812

Nov 26, 2024 07:32AM Cognition Therapeutics (CGTX) Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Nov 13, 2024 07:31AM Cognition Therapeutics, Inc. (CGTX) Misses Q3 EPS by 5c

Nov 4, 2024 06:49AM H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)

Oct 29, 2024 12:57PM Cognition Therapeutics (CGTX) Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Aug 22, 2024 07:32AM Cognition Therapeutics (CGTX) Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

Aug 8, 2024 08:18AM Cognition Therapeutics, Inc. (CGTX) Tops Q2 EPS by 5c

Aug 6, 2024 07:32AM B.Riley Downgrades Cognition Therapeutics (CGTX) to Neutral

Jul 31, 2024 06:42AM Cognition Therapeutics (CGTX) PT Lowered to $7 at H.C. Wainwright

Jul 29, 2024 07:01AM Cognition Therapeutics' (CGTX) Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients

Jul 29, 2024 06:56AM Cognition Therapeutics, Inc. (CGTX) Halted, News Pending

Jul 2, 2024 07:32AM Cognition Therapeutics (CGTX): Results from Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC